SARS-CoV-2 Eta variant
Variant of SARS-CoV-2
This article is about the variant of SARS-CoV-2. For the Greek letter, see Eta (letter).
The SARS-CoV-2 Eta variant is one of the variants of the virus SARS-CoV-2, which causes the disease COVID-19. This variant is also known by its Pango lineage designation as B.1.525. It was first identified in December 2020 and has since been detected in multiple countries around the world.
Genetic characteristics[edit | edit source]
The Eta variant is characterized by several mutations in the spike protein of the virus, which is the primary target for COVID-19 vaccines. Notable mutations include E484K, which is associated with reduced neutralization by some antibodies, and the deletion 69-70del, which is also found in other variants of concern such as the Alpha variant. These mutations may affect the transmissibility and immune escape potential of the virus.
Epidemiology[edit | edit source]
The Eta variant was first identified in the United Kingdom and Nigeria in December 2020. Since then, it has been reported in several other countries, including the United States, Denmark, and Canada. The spread of the Eta variant has been monitored by global health organizations to assess its impact on public health.
Impact on public health[edit | edit source]
The presence of the Eta variant has raised concerns due to its mutations, which may affect vaccine efficacy and the effectiveness of monoclonal antibody treatments. However, studies are ongoing to determine the exact impact of these mutations on the clinical outcomes of COVID-19.
Vaccine efficacy[edit | edit source]
Preliminary data suggest that the Eta variant may have some degree of resistance to neutralization by antibodies generated by current vaccines. However, vaccines are still expected to provide protection against severe disease and hospitalization. Ongoing research is crucial to fully understand the implications of the Eta variant on vaccine performance.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
